Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 7Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 4Neuroblastoma 3Neoplasm Metastasis 3Hematologic Neoplasms 3Granuloma, Plasma Cell 3Melanoma 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, B-Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1ALK-positive Advanced Tumors 1

Interventions

Crizotinib 2lorlatinib 1ceritinib 1brigatinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK-positive NSCLC × ceritinib × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡